Treatment or Psoriasis with Calcipotriene and Betamethasone Dipropionate (CAL/BDP) Cream Showed Significantly Higher Proportion of Patients with an Absolute mPASI≤2 Compared to CAL/BDP Gel/Topical Suspension in a Post-Hoc Aanalysis of Two Phase 3 Studies
Main Article Content
Keywords
psoriasis, topical, calcipotriene, betamethasone, cream
References
2. Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, et al. Psoriasis treat to target: defininf outcomes in psoriasis using data from real-world population-based cohort study (the British Assosciation of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol.2020;182(5):1158-66.
3. Puig L. Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of Ixekizumab to Etanercept and placebo in patients with moderate-to-severe plaque psoriais: An integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol.2019;99(11):971-7.
4. Gerdes S, Korber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis and severity (PASI) treatment goals and their assosciation with health-related quality of life. J Dermtolg Treat.2020;31(5):470-5.
5. Stein Gold et al. J Drugs Dermatol. 2021 Apr 1;20(4):420-425. doi: 10.36849/JDD.2021.5653.
6. Pinter A, Reich A, Arenberger P, et al. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis [published online ahead of print, 2023 Jul 11]. J Eur Acad Dermatol Venereol. 2023;10.1111/jdv.19330. doi:10.1111/jdv.19330
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.